This adjuvant treatment approach allowed us to evaluate the role of SHP2 specifically in the progression of established metastatic tumors, as we initiated SHP2 inhibitor treatments or doxycycline induced depletion of SHP2 only after tail vein injection or primary tumor removal and once metastases were seeded. This evidence concerns the gene PTPN11 and metastatic neoplasm.